kriti singh

kriti singh

Followers 0
Following 0
The global bioprocess containers market is expected to reach USD 1,914.6 million by 2023 from USD 913.3 million in 2017, at a CAGR of 13.2%.The base year considered for the study is 2017, and the forecast for the market is provided for the period between 2018 and 2023.Growth in the bioprocess containers market is mainly driven by factors such as the increasing demand for biologics, affordability and sustainability of single-use bioprocess technologies, vaccine production using single-use disposable technologies, and the lower risk of cross-contamination.The booming biopharma industry in emerging countries is also expected to offer a wide range of growth opportunities to players in the market.On the other hand, issues related to leachable and extractables and increasing market consolidation are expected to challenge market growth to a certain extent during the forecast period.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832Market DynamicsDriver: Rising Demand for Low-Cost Biologic DrugsAt present, there is a rising demand for low-cost biologic drugs.A major factor driving the biologics market is the rapidly increasing global geriatric population.According to the US Census Bureau, in 2015, an estimated 8.5% (or 617.1 million individuals) of the global population was aged 65 years and older; by 2030, this figure is estimated to reach 22%.In the same year, the aging population accounted for 18.6% of the total population in the US and 18.9% of the total population in Europe.Opportunity: Booming Emerging MarketsChina, India, Japan, Korea, and Brazil are emerging markets for single use bioprocessing systems.
Factors driving the growth of this market include the rising incidence of target indications; availability of funding for stem cell research; technological advancements in stem cell research instruments; and growth of end-use industries.The stem cell assay market was valued at USD 660.9 Million in 2017 and is expected to reach USD 1,978.7 Million by 2023, at a CAGR of 20.1%.Selected Market Dynamics in Stem Cell Assay Market Growth of end-use industries The growth of the stem cell assays market corresponds with that of the biotechnology and biopharmaceutical industries, as these form significant end users for stem cell research products.The continuation of this trend—the growth of the end-user base—has compelled a number of companies to launch new products and invest in stem cell-based therapies.According to estimates from the Deloitte Touche Tohmatsu Limited (DTTL) Life Sciences and Health Care Industry Group, biotech drugs (vaccines, biologics) continue to gain traction in the life sciences sector.Of the top ten pharmaceutical products (by sales) in 2014, the majority were biotech drugs.Biotech drug sales were estimated at USD 289 billion in 2014, and this figure is projected to grow to USD 445 billion by 2019.Moreover, biotech drugs accounted for a share of 18% of the total sales of drugs in 2010, which is expected to increase to 26% by 2019.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47610330Ethical issues related to embryonic stem cell research Research in cell biology necessitates the use of animals and humans, as animal and human cells are used in gene therapy studies that involve the recombination of genes and stem cell research therapies.These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs that may harm animals and humans.In addition, stem cell research studies use human embryos for clinical applications that often lead to the destruction of the embryos.
1
The infertility treatment market is expected to grow from USD 1.5 billion in 2018 to USD 2.2 billion by 2023, at a compound annual growth rate (CAGR) of 8.0% during the forecast period.Market Dynamics Growth in the infertility treatment market is primarily driven by factors such as the declining global fertility rate; rising number of fertility clinics worldwide; technological advancements; and increasing public-private investments, funds, and grants.Growth opportunities in emerging markets and the use of fertility treatment options by single parents and same-sex couples are also expected to provide opportunities for players in this market.On the other hand, the high procedural cost of assisted reproductive techniques in developed markets and unsupportive government regulations for certain infertility treatment options are expected to limit market growth to a certain extent.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43497112Driver: Declining fertility rate Infertility is the inability of an individual to achieve clinical pregnancy.Fertility rates measure the average number of children per woman.The fertility rate worldwide is declining steadily owing to various factors such as the growing trend of late marriages and increasing age-related infertility.Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050.
2
The global life science instrumentation market size is projected to grow from an estimated USD 60.0 billion in 2020 to USD 79.9 billion by 2025, at a CAGR of 5.9% during the forecast period.Market growth is driven largely by factors, such as increasing expenditure on research & development by pharmaceutical & biotechnology companies, growing public & private funding for life science research, and rising incidence of target diseases & genetic disorders.The emerging markets and increasing demand for analytical instruments are expected to present avenues of growth for market players.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=38By technology, the next-generation sequencing segment is expected to grow at the highest rate during the forecast period Based on technology, the life science instrumentation market is segmented into spectroscopy, chromatography, PCR, immunoassays, lyophilization, liquid handling, clinical chemistry analyzers, microscopy, flow cytometry, next-generation sequencing (NGS), centrifuges, electrophoresis, cell counting, and other technologies.The next-generation sequencing (NGS) segment is expected to grow at the highest CAGR during the forecast period, attributed to the advantages offered by NGS technologies in DNA sequencing, which substantially provides more throughput and minimizes the need for fragment-cloning methods.By type, the molecular spectroscopy segment was the largest contributor to the spectroscopy technologies market in 2019 The market for spectroscopy technologies, by type, comprises mass spectrometry, molecular spectrometry, and atomic spectrometry.Molecular spectrometry accounted for the largest share of the spectrometry technologies market in 2019.The large share could be attributed to the wide application of this technology and the presence of stringent regulatory guidelines for drug development and safety.Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=38Asia Pacific is expected to grow at the highest CAGR in the life science instrumentation market during the forecast periodThe Asia Pacific is one of the major revenue-generating regions in the life science instrumentation industry.The strategic expansions by key market players in emerging Asian countries, the growing pharmaceutical industry in India & China, and conferences, exhibitions, & meetings on analytical instruments is driving growth in the region.Key Market Players The vendors operating in the global life science instrumentation market include Agilent Technologies (US), Becton, Dickinson, and Company (US), Bio-Rad Laboratories, Inc. (US), Bruker Corporation (US), Danaher Corporation (US), Eppendorf AG (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Horiba (Japan), Merck KGaA (Germany), PerkinElmer, Inc. (US), Qiagen N.V. (Netherlands), Shimadzu Corporation (Japan), Thermo Fisher Scientific, Inc. (US), and Waters Corporation (US).Recent Developments:In 2019, Danaher Corporation (US) signed an agreement with GE Healthcare (US).
3
The global professional dental care market is estimated to grow at a CAGR of 4.5% from 2016 to 2021 to reach USD 961.0 Million by 2021.Factors such as growing number of small/ private dental clinics, rising incidences of dental caries, increasing disposable incomes in emerging countries, growing awareness about dental hygiene, and economic gains for dental practitioners are the major factors driving the growth of the global market.However, increasing number of large/group dental practices and reluctance to adopt dental dispensing practices by dental practitioners are expected to restrain the growth of this market to certain extent.Market DynamicsGrowing number of small/private dental clinicsIn recent years, there has been a significant increase in the number of dentists across the globe, owing to which, the number of dental practices has also increased.The US is one of the major markets for dental dispensing products mainly due to the large number of dental practices in the country, increasing expenditure on dental care, and widespread awareness about oral hygiene.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210346692APAC, on the other hand, is the fastest-growing region for the Oral Care products market mainly due to the increasing number of dentists and dental practices in the region, growing disposable incomes, and rising awareness about oral hygiene.In India, every year, approximately 12,000 to 15,000 new practices are started in the country.Similarly, the number of dentists in China increased from around 111,000 in 2010 to 137,100 in 2015.Toothbrush segment to register highest growthIn this report, the professional dental care products market is segmented on the basis of type-of-product, and region.On the basis of product type, the market is segmented into toothpastes, toothbrushes, mouthwashes/rinses, denture products, dental accessories/ancillaries, and other professional dental care products.
1
The global operating room management market size is expected to reach USD 4.4 billion by 2025 from USD 2.4 billion in 2020, at a CAGR of 12.4%.Growth in this market can be attributed to factors such as the emphasis on cost control and efficiency improvement in hospitals, growing adoption of EHRs and other HCIT solutions, favorable government support, redevelopment projects, and the availability of funding to promote OR infrastructure.However, a dearth of skilled surgeons in integrated operating rooms and the high prices and maintenance costs of ORM software are expected to hinder the market growth.Operating Room Management Market Dynamics Drivers: Increasing emphasis on cost control and efficiency improvement in hospitals The overall cost of healthcare delivery has grown significantly over the last few decades, mainly due to increasing health insurance premiums, the rising demand for quality healthcare services, rising geriatric population, and the increasing incidence of chronic disorders.Another important factor attributing to rising healthcare costs is the high dependency on traditional and outdated methods such as paper-based patient records, which leads to an increase in readmission rates, medical errors, and administration costs.To know about the assumptions considered for the study, download the pdf brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=175407912Restrains: High pricing and maintenance costs of ORM software The adoption of ORM solutions has been particularly affected by its high installation and maintenance costs.ORM software, when once installed, also requires to be regularly updated as per the user’s requirement and software enhancements, thereby presenting recurring expenditure.Additionally, the maintenance of high-end IT-enabled systems typically costs more than the software itself.Opportunities: Emerging markets and growing medical tourism Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world.The number of independent health care providers has been decreasing as most healthcare providers are turning to mergers, acquisitions, and partnerships and are functioning under a health system rather than operating independently.On a 15-year basis, the percentage of hospitals functioning under a health system has increased from approximately 50% to approximately 65%.Asia Pacific to witness significant growth from 2020 to 2025 Geographically, the operating room management market is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the World.
The breast lesion localization methods Market is expected to grow from 3,974.4 thousands of procedures in 2020 to 5750.9 thousands of procedures by 2025, at a CAGR of 7.5% during the forecast period.The growth of this market is primarily driven by factors such as the rising incidence of breast cancer, an increasing number of breast cancer surgeries, and growing awareness on the early detection of breast cancer.However, the uncertain regulatory approval process faced by prominent players is hampering the growth of the breast lesion localization methods market.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=35768623Breast lesion localization methods Market Dynamics DRIVER: GROWING INCIDENCE OF BREAST CANCER Globally, there has been a significant growth in the number of breast cancer cases.This can majorly be attributed to changing lifestyles, increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement.Following are some major statistics in this regard: In the US, one in eight women develop invasive breast cancer over the course of their lifetime.RESTRAINT: UNCERTAINTY IN REGULATORY APPROVAL PROCEDURES Breast localization devices are Class II and III medical devices, and have to undergo a stringent regulatory procedure in order to be approved by the FDA.In the US, it takes around 3 to 7 years to prove the medical safety of any new device.As per law, even a new size of a previously approved device needs to go through the entire process before commercialization.Opportunity: EMERGING ECONOMIES OFFER HIGH GROWTH POTENTIAL Governments in emerging countries are also investing heavily in the development and modernization of healthcare infrastructure.For instance, healthcare expenditure in China increased in 2016, as fiscal spending on healthcare grew by 10% year-on-year.
The global dental 3D printing market is projected to reach USD 6.5 billion by 2025 from 1.8 billion in 2020, at a CAGR of 28.8% during the forecast period.The dental 3D printing medical devices market is primarily driven by factors such as the high incidence of dental caries and other dental diseases, rising demand for cosmetic dentistry, the growing adoption of dental 3D printers in hospitals and clinics, and rapid growth in the geriatric population.On the other hand, the rising number of large dental practices is expected to limit market growth to a certain extent.To know about the assumptions considered for the study, Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=258228239The services segment holds the highest market share, by product & service, in the forecast period.On the basis of product & service, the dental 3D printing market is broadly segmented into services, materials and equipment.The equipment segment is further divided into dental scanners and printers.The large share of the services segment can be attributed to the competitive pricing offered by dental 3D printing service providers and the large-scale outsourcing of dental product design and production by small hospitals, dental clinics, and laboratories.Based on technology, fused deposition modeling is projected to grow at the highest CAGR in the forecast periodBased on technology, the dental 3D printing market is segmented into VAT photopolymerization, fused deposition modeling, selective laser sintering, PolyJet printing, and other technologies.The fused deposition modeling segment is projected to register the highest growth rate in the dental 3D printing market, by technology during the forecast period.In dentistry, FDM is a widely applied technology due to the availability of a wide range of biocompatible, strong, and sterilizable thermoplastics.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258228239Based on application, prosthodontics holds the highest market share in the dental 3D printing marketOn the basis of application, the 3D printing in dentistry market is segmented into prosthodontics, implantology and orthodontics.
The report "Hemostats Market by Product (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Gynecology, Neurology, Cardiovascular, Reconstructive), Formulation (Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2023", The hemostats market is expected to reach USD 3.03 billion by 2023 from USD 2.27 billion in 2018, at a CAGR of 6.0%.Growth in this market is driven by the increasing number of surgical procedures, growing number of regulatory approvals, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries.In addition, the emerging markets and growth in the number of hospitals and surgical centers are expected to offer further growth opportunities for players operating in the hemostats market.On the other hand, high cost of hemostats and dearth of skilled professionals are expected to hinder the growth of this market.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619The thrombin-based hemostats segment is expected to account for the largest share of the market in 2018.Based on product, the hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats.Of all these product segments, the thrombin-based hemostats segment is expected to account for the largest share of the global hemostats market in 2018.In 2018, the orthopedic surgery segment is expected to dominate the hemostats market On the basis of application, the hemostats market is segmented neurological surgery, cardiovascular surgery, general surgery, orthopedic surgery, gynecological surgery, reconstructive surgery, and other surgeries.The orthopedic surgery segment is expected to account for the largest share of the hemostats market in 2018.In 2018, North America to command for the largest market share On the basis of region, the hemostats market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.In 2018, North America is expected to account for the largest share of the global hemostats market.
The Creatinine Measurement Market is expected to reach USD 700.8 million by 2027 from USD 377.2 million in 2018, at a CAGR of 8.4%.The increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rising geriatric population, and increasing number of drug development initiatives are the key drivers for global creatinine measurement market.The Jaffe’s kinetic method segment is expected to hold the largest in the market in 2018The creatinine test kits and regents market, by test type, is segmented into the Jaffe’s kinetic method and enzymatic method.In 2018, the Jaffe’s kinetic method segment is expected to hold the largest share of the creatinine measurement market.The widespread availability and cost-effectiveness of kits and reagents used in Jaffe’s kinetic method is a key factor driving the growth of creatinine test kits and regents market.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206847385Based on the type of sample, the blood/serum segment is expected to register the highest CAGR during the forecast periodBased on type of sample the creatinine test kits and regents market is segmented into blood/serum and urine samples.The blood/serum segment is expected to witness the highest CAGR over the forecast period.Most creatinine measurement kits and reagents are based on the analysis of creatinine in blood samples owing to its accuracy in inferring creatinine concentration and low risk of contamination.North America to dominate the creatinine test kits marketIn 2018, North America is expected to dominate the creatinine test kits market followed by Europe.
The Report "Bioprocess Containers Market by Type (2D Bags, 3D Bags, Tank Liners), Application (Process Development, Upstream, and Downstream), End Users (Biopharmaceutical, and Life Science Companies), and Region - Global Forecast to 2023", The Bioprocess Containers Market is expected to reach USD 1,914.6 Million by 2023 from USD 1,030.0 Million in 2018, at a CAGR of 13.2%.The major factors driving the growth of this market include the lower risk of cross-contamination, high adoption of bioprocess containers over stainless steel equipment, and increasing adoption of single-use technology in the manufacturing process of biopharmaceuticals.Growth in the bioprocess containers market is mainly driven by factors such as the increasing demand for biologics, affordability and sustainability of single-use bioprocess technologies, vaccine production using single-use disposable technologies, and the lower risk of cross-contamination.The booming biopharma industry in emerging countries is also expected to offer a wide range of growth opportunities to players in the market.On the other hand, issues related to leachable and extractables and increasing market consolidation are expected to challenge market growth to a certain extent during the forecast period.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832Biopharmaceutical Companies is expected to account for the largest share for Bioprocess Containers Market Based on end user, the biocontainers market is segmented into biopharmaceutical companies and life science R companies.The biopharmaceutical companies’ segment is expected to dominate the market during the forecast period, while the life science R companies segment is expected to grow at the highest CAGR.Biopharmaceutical manufacturing is generally characterized using single-use technologies including bioprocess containers.Bioprocess container systems, due to their cost-effectiveness, have found wide use in biopharmaceutical manufacturing as they can lower the overall cost of production.This is the key factor driving market growth for the biopharmaceutical companies’ segment.North America is estimated to command the largest share of the market North America accounted for the largest share of this market in 2017, followed by Europe.
The report studies the global occlusion devices market over the forecast period of 2018 to 2023.The market is projected to reach USD 3.55 Billion by 2023 from USD 2.74 Billion in 2018, at a CAGR of 5.3%.Factors such as the growth in target patient population, technological advancements, favorable reimbursement scenario for minimally invasive surgeries, and the availability of clinical evidence for the safety and efficacy of occlusion procedures are driving the growth of the occlusion devices market.Based on product, the occlusion removal devices segment is estimated to have the largest share of the market in 2018.On the basis of product, the embolization devices market is segmented into occlusion removal devices (balloon occlusion devices, stent retrievers, coil retrievers, and suction and aspiration devices), embolization devices (embolic coils and liquid embolic agents), tubal occlusion devices, and support catheters (microcatheters and guidewires).Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249840809Based on application, the neurology segment is expected to account for the largest share of this market in 2018.On the basis of application, the occlusion removal devices market is categorized into neurology, cardiology, peripheral vascular diseases, urology, oncology, and gynecology.Neurology applications are expected to account for the largest share of the embolization devices market in 2018.North America is expected to dominate the occlusion removal devices market in 2018.Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period.The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R spending & healthcare expenditure.Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years.However, quality concerns over antibodies are the major challenge in this market.To know about the assumptions considered for the study, Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=255585571The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast periodThe Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories.The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020.The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.Indirect immunofluorescence segment accounted for the highest CAGRBased on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence.The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.Cancer accounted for the largest share of the immunofluorescence assay market in 2020Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases.
The global medical ceramics market is projected to reach USD 12.9 billion by 2025 from USD 9.6 billion in 2020, growing at a CAGR of 5.9% from 2020 to 2025.Increasing research activities for the development of novel medical ceramics, growing demand for medical ceramics in plastic surgeries & wound healing applications; the rising number of hip & knee replacement procedures; and the increasing demand for implantable devices are responsible for the significant growth of the medical ceramics market during the review period.“Bioinert Ceramics: The largest segment of medical ceramics market”Based on the type of material, the global medical ceramics market is segmented into bioinert ceramics, bioactive ceramics, bioresorbable ceramics, and piezoceramics.Bioinert ceramics exhibit high fracture toughness, low thermal conductivity, excellent resistance to wear & corrosion, and extremely high bending & tensile strength.Bioinert ceramics are widely used in the orthopedic & dental industry.“Zirconia: The largest segment of bioinert ceramcs market”Based on type, the global bioinert ceramics market is segmented into zirconia, alumina, and other bioinert ceramics (titanium, pyrolytic carbon, and silicon nitride).This can be attributed to the advantages of zirconia over other ceramic materials, the rising demand for aesthetically attractive dental restorations, the launch of new & advanced products, and growing research activities to develop novel products.Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=237425129“Hydroxyapatite: The largest segment of bioactive ceramics market”Based on type, the global bioactive ceramics market is segmented into hydroxyapatite and glass ceramics.Hydroxyapatite has high biocompatibility, bioactivity, and osteoconductivity; making it suitable for a wide range of applications, such as a bone void filler for the orthopedic, spine, maxillofacial, and dental surgery; restoration of periodontal defects; orthopedic and dental implant coating; bone-tissue engineering; and gene delivery.Due to its bioactivity, hydroxyapatite is an alternative to allogenic & xenogeneic bone grafts, resulting in shorter healing times.
The Healthcare Fraud Analytics Market is projected to reach USD 4.6 billion by 2025 from USD 1.2 billion in 2020, at a CAGR of 29.8% during the forecast period.Market growth can be attributed to the large number of fraudulent activities in healthcare; the increasing number of patients seeking health insurance; high returns on investment; and rising pharmacy claim-related frauds.However, the dearth of skilled personnel is likely to restrain the growth of this market.The prescriptive analytics segment registered the highest growth during the forecast period.Fraud analytics solutions vary from vendor to vendor.Some vendors offer rule-based models while others offer AI-based technologies, but broadly, these solutions are classified based on the type of analytics used—descriptive analytics, predictive analytics, and prescriptive analytics.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=221837663 In 2019, public & government agencies accounted for the largest share of the healthcare fraud analytics market, by end user.Based on end user, the healthcare fraud detection market is segmented into public & government agencies, private insurance payers, employers, and third-party service providers.The public & government agencies segment accounted for the largest share of the healthcare fraud analytics market in 2019.North America dominated the market in 2019 North America accounted for the largest share of the healthcare fraud analytics market in 2019, followed by Europe.Factors such as the high number of cases of healthcare fraud, including pharmacy-related fraud, favorable government initiatives, technological advancements, and the availability of solutions in this region are some factors contributing to North America’s large share in the global healthcare fraud analytics space.Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=221837663Leading CompaniesIBM Corporation (US), Optum (US), SAS Institute (US), Change Healthcare (US), EXL Service Holdings (US), Cotiviti (US), Wipro Limited (Wipro) (India), Conduent (US), HCL (India), Canadian Global Information Technology Group (Canada), DXC Technology Company (US), Northrop Grumman Corporation (US), LexisNexis Group (US), and Pondera Solutions (US).Key Questions Addressed in the Report Who are the top 10 players operating in the global healthcare fraud analytics market?What are the drivers, restraints, opportunities, and challenges in the market?What are the industry and technology trends in the market?What are the growth trends in the healthcare fraud analytics market at the segmental and overall market levels?To speak to our analyst for a discussion on the above findings, click Speak to Analyst
The Preparative and process chromatography market size is expected to reach USD 8.60 billion by 2023 from the estimated USD 6.27 billion in 2018, at a CAGR of 6.5%.The major factors driving the growth of this market are the increasing prevalence of appendicitis and growing preference for R investments in biotechnology and pharmaceutical companies.Emerging economies such as India, China, and Brazil provide opportunity for the players operating in the process and preparative market.However, high cost of instrument and availability alternative techniques for purification and separation of pharmaceutical products are the major restraining factors for this market.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151748164“The biotechnology and pharmaceutical industries segment dominated the market in 2018.” Based on end user, the process and preparative chromatography market has been segmented into biotechnology and pharmaceutical industries; food and nutraceutical industries; and academic research laboratories.The biotechnology and pharmaceutical industries segment is estimated to account for the largest share of the overall market in 2018.“The process chromatography segment is estimated to grow at a rapid rate during the forecast period.” Based on type, the preparative chromatography market has been segmented into two segments, namely, process chromatography and preparative chromatography.Each segment has been further divided based on products and service.During the forecast period, the process chromatography segment is estimated to register the higher growth rate in the overall process and preparative chromatography market.Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=151748164“Asia Pacific is estimated to register the highest CAGR during the forecast period.” In this report, the process and preparative chromatography market is segmented into four major regional segments—North America, Europe, Asia Pacific, and the Rest of the World.The process and preparative chromatography market in Asia Pacific is projected to register the highest growth rate during the forecast period.Leading CompaniesGE Healthcare (US), Merck KGaA (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), Thermo Fisher Scientific (US), Agilent Technologies (US), Novasep Holding S.A.S (France), Waters Corporation (US), Daicel Corporation (Japan), and Shimadzu Corporation (Japan).Key Developments In 2017, GE Healthcare introduced a new Protein A chromatography resin, MabSelect PrismA for monoclonal antibodies purificationIn 2017, Merck introduced Eshmuno P Anti-A and Anti-B Chromatography Resins used in the manufacturing of plasma-derived immunoglobulin (Ig) therapiesTo speak to our analyst for a discussion on the above findings, click Speak to Analyst
Factors driving the growth of this market include the rising incidence of target indications; availability of funding for stem cell research; technological advancements in stem cell research instruments; and growth of end-use industries.The stem cell assay market was valued at USD 660.9 Million in 2017 and is expected to reach USD 1,978.7 Million by 2023, at a CAGR of 20.1%.Selected Market Dynamics in Stem Cell Assay MarketGrowth of end-use industriesThe growth of the stem cell assays market corresponds with that of the biotechnology and biopharmaceutical industries, as these form significant end users for stem cell research products.The continuation of this trend—the growth of the end-user base—has compelled a number of companies to launch new products and invest in stem cell-based therapies.According to estimates from the Deloitte Touche Tohmatsu Limited (DTTL) Life Sciences and Health Care Industry Group, biotech drugs (vaccines, biologics) continue to gain traction in the life sciences sector.Of the top ten pharmaceutical products (by sales) in 2014, the majority were biotech drugs.Biotech drug sales were estimated at USD 289 billion in 2014, and this figure is projected to grow to USD 445 billion by 2019.Moreover, biotech drugs accounted for a share of 18% of the total sales of drugs in 2010, which is expected to increase to 26% by 2019.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47610330Ethical issues related to embryonic stem cell researchResearch in cell biology necessitates the use of animals and humans, as animal and human cells are used in gene therapy studies that involve the recombination of genes and stem cell research therapies.These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs that may harm animals and humans.In addition, stem cell research studies use human embryos for clinical applications that often lead to the destruction of the embryos.
 The global sepsis diagnostics market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness.The blood culture segment accounted for the largest share of the market, by technology, in 2019The sepsis diagnostics market, by technology, the market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers.In 2019, the blood culture segment accounted for the largest share of the market.This share can be attributed to the low cost of microbiology techniques and the extensive use of blood culture methods for the diagnosis of sepsis.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155The hospitals end-user segment accounted for the largest share of the sepsis diagnostics market in 2019Based on end-user, the market is segmented into hospitals, pathology & reference laboratories, and research laboratories & academic institutes.In 2019, hospitals accounted for the largest share of the sepsis diagnostics industry.The large share of this segment can be attributed to the high prevalence of sepsis coupled with a large number of fatalities caused by the illness, and in-house hospital laboratories perform a large number of blood culture tests to identify BSIs (caused by bacteria, fungi/yeast, or viruses).North America accounted for the largest share of the global sepsis diagnostics market in 2019North America is a well-established sepsis diagnostic industry  for medical devices.The presence of a highly developed healthcare system, high adoption of innovative sepsis diagnostic technologies among medical professionals, increasing sepsis incidences performed in the region, and technological advancements in the field of sepsis diagnostics are the major factors driving the market in North America.Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155Leading CompaniesSome of the players in the sepsis diagnostics market are bioMérieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), and CytoSorbents (US).
The healthcare supply chain management market size is projected to reach USD 3.3 billion by 2025 from USD 2.2 billion in 2020, at a CAGR of 7.9% during the forecast period.The key factors driving the growth of this market include the adoption of GS1 system of standard in the healthcare industry globally, the emergence of cloud-based solutions, reduction in operational costs by improving the efficacy and increase in overall profitability.However, the high cost of implementation of supply chain management software is expected to restrict market growth to a certain extent.By component, the software segment accounted for the largest market share in 2019.Based on the component, the market is bifurcated into hardware and software segments.The software segment commanded the largest share of the global healthcare supply chain management market in 2019.The large share of this segment can be attributed to the increasing number of online purchases, improving business intelligence, and growing preference for eco-friendly logisticsDownload a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77439622The on-premise segment commanded the largest share of the healthcare supply chain management industry, by delivery mode, in 2019.Based on delivery mode, the market is segmented into on-premise and cloud-based.The on-premise segment accounts for the largest share of the healthcare supply chain management market.However, the cloud-based segment is expected to register the highest growth over the forecast period.North America dominates the healthcare supply chain management industry during the forecast period.The medical supply chain management market is segmented into North America, Europe, the APAC, and the RoW.
The global healthcare asset management market is projected to reach USD 35.19 billion by 2023 from USD 8.98 billion from 2018, at a CAGR of 31.4%.Need for better asset management in hospitals, acceptance of asset management solutions in pharmaceutical industry, and decline in prices of RFID Tags are the factors driving the growth of the healthcare asset management market.RFID Tags segment is expected to dominate the RFID products market in 2018.Based on type, the healthcare asset management market is segmented into tags, readers/interrogators, antennas, and accessories.In 2018, the RFID tags segment is expected to dominate the market.The growth of this market is attributed to the increasing acceptance of RFID in pharmaceutical companies, declining prices of RFID tags, and the availability of technologically advanced products in the market.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1195Based on type, the passive RFID tag segment is projected to grow at the highest CAGR during the forecast period.Based on type, RFID tags market is segmented into passive tags and active tags.In 2018, the passive RFID segment is expected to account for the largest share of the market; also, this segment is expected to register highest CAGR during the forecast period owing to the low cost of passive tags in comparison with active tags.Also, passive tags do not require an external source of energy, owing to which they are more widely adopted.North America to dominate the healthcare asset market in 2018 In 2018, North America is expected to dominate the hospital asset management market followed by Europe.
More

Top